Self-reported use, outcomes and adverse events of GLP-1 and research peptides on Reddit, 2026

Background: People now discuss and use not only approved incretin drugs (tirzepatide, semaglutide) but also retatrutide, which is still investigational, and unapproved "research peptides" such as BPC-157, TB-500, GHK-Cu and MOTS-c, often sourced outside regulated supply. These products sit outside routine safety monitoring. Methods: We analysed 3,092 public Reddit posts by 2,706 authors in 19 subreddits (7 June – 31 October 2026). A large language model (claude-haiku-4-5) coded each post against a fixed codebook for compounds, topic, self-reported outcome, duration, supply channel and adverse events (MedDRA-style terms). Coding was validated against a blind 250-post reference set (topic κ = 0.67, outcome κ = 0.61) and a blind pharmacist sample of 20 posts (adverse-event precision 0.81, recall 0.72). Posts by apparent minors were excluded. Results: 1,620 posts (52.4%) were first-hand reports. Among posts stating an outcome, the drug "worked" in 38.3% for tirzepatide, 31.0% for retatrutide and 23.7% for semaglutide; partial response was most common for all three. Nausea was the leading adverse event for the approved drugs (19.8% of first-hand semaglutide posts, 12.5% for tirzepatide). Retatrutide posts reported increased heart rate (3.7% vs 1.4%) and insomnia (4.4% vs 2.1%) more often than tirzepatide posts. Where a source was stated, 66.1% of retatrutide reports named a research-chemical supplier, against 8.7% for tirzepatide. Conclusions: Adverse-event profiles reported online match the trials for the approved drugs and show early signals for retatrutide, which is used largely outside regulated supply. Validated, AI-coded social listening can support safety monitoring before a drug is approved. Data: aggregate dataset at https://doi.org/10.5281/zenodo.24363468

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-19
DOI
https://doi.org/10.5281/zenodo.24363802
Primary Topic
Pharmacovigilance and Adverse Drug Reactions
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Self-reported use, outcomes and adverse events of GLP-1 and research peptides on Reddit, 2026

Marko Maal
Zenodo (CERN European Organization for Nuclear Research)
Pharmacovigilance and Adverse Drug Reactions
preprint

Self-reported use, outcomes and adverse events of GLP-1 and research peptides on Reddit, 2026

Marko Maal
preprint en

Abstract

Background: People now discuss and use not only approved incretin drugs (tirzepatide, semaglutide) but also retatrutide, which is still investigational, and unapproved "research peptides" such as BPC-157, TB-500, GHK-Cu and MOTS-c, often sourced outside regulated supply. These products sit outside routine safety monitoring. Methods: We analysed 3,092 public Reddit posts by 2,706 authors in 19 subreddits (7 June – 31 October 2026). A large language model (claude-haiku-4-5) coded each post against a fixed codebook for compounds, topic, self-reported outcome, duration, supply channel and adverse events (MedDRA-style terms). Coding was validated against a blind 250-post reference set (topic κ = 0.67, outcome κ = 0.61) and a blind pharmacist sample of 20 posts (adverse-event precision 0.81, recall 0.72). Posts by apparent minors were excluded. Results: 1,620 posts (52.4%) were first-hand reports. Among posts stating an outcome, the drug "worked" in 38.3% for tirzepatide, 31.0% for retatrutide and 23.7% for semaglutide; partial response was most common for all three. Nausea was the leading adverse event for the approved drugs (19.8% of first-hand semaglutide posts, 12.5% for tirzepatide). Retatrutide posts reported increased heart rate (3.7% vs 1.4%) and insomnia (4.4% vs 2.1%) more often than tirzepatide posts. Where a source was stated, 66.1% of retatrutide reports named a research-chemical supplier, against 8.7% for tirzepatide. Conclusions: Adverse-event profiles reported online match the trials for the approved drugs and show early signals for retatrutide, which is used largely outside regulated supply. Validated, AI-coded social listening can support safety monitoring before a drug is approved. Data: aggregate dataset at https://doi.org/10.5281/zenodo.24363468

Zenodo (CERN European Organization for Nuclear Research)
Pharmacovigilance and Adverse Drug Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon